Compare ING Groep NV (ING) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ING Groep NV vs Novo Nordisk A/S — how do they compare? ING Groep NV trades at $35.49 (market cap $101.22B), while Novo Nordisk A/S trades at $45.8 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 2.1× ING Groep NV's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| ING | NVO | |
|---|---|---|
Market Cap | $101.22B | $207.85B |
Sector | Financials | Health |
52-Week High | $35.92 | $63.98 |
52-Week Low | $23.66 | $35.29 |
Dividend Yield | 3.73% | 3.81% |
Enterprise Value | — | $222.55B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
